Dental Carotid Cognitive Study
Palabras clave
Abstracto
Descripción
Periodontal Disease (PD) is present in 60+% of adults >65 years and is associated with tobacco smoking, diabetes, and atherosclerosis that worsen inflammation, comorbidities common in older people with mild to moderate cognitive impairment (MCI). Older MCI patients are prone to poor oral hygiene and dental health, which if untreated worsens inflammation-mediated brain and nervous system function, and accelerates progression to dementia. Asymptomatic carotid artery stenosis (ACAS) is often a silent disease detected in only ~10% of older adults, and may have a strong association with MCI. This study examines the effects of intensive therapy for periodontitis on cognition in high-risk older people with ACAS. Results could highlight PD as a readily modifiable risk factor for dementia.
This pilot study examines the hypothesis that intensive treatment of PD (IPT) in older people with MCI and ACAS will attenuate their cognitive decline by reducing oral microbial-mediated inflammation and improving cerebrovascular endothelial function that contribute to neurodegeneration-associated dementia.
The aims are to determine the effects of intensive compared to control PD treatment (randomized: IPT vs. CPT) in 60 MCI subjects with ACAS and PD on 1) Cognitive function (Primary Outcome) and quality of life (Secondary Outcome), and 2) The potential mechanisms mediating these effects
fechas
Verificado por última vez: | 08/31/2019 |
Primero enviado: | 11/11/2018 |
Inscripción estimada enviada: | 11/25/2018 |
Publicado por primera vez: | 11/27/2018 |
Última actualización enviada: | 09/10/2019 |
Última actualización publicada: | 09/11/2019 |
Fecha de inicio real del estudio: | 04/07/2019 |
Fecha estimada de finalización primaria: | 10/30/2020 |
Fecha estimada de finalización del estudio: | 10/30/2021 |
Condición o enfermedad
Intervención / tratamiento
Procedure: Standard treatment (control)
Procedure: Intensive Treatment
Fase
Grupos de brazos
Brazo | Intervención / tratamiento |
---|---|
Active Comparator: Standard treatment (control) Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction. | Procedure: Standard treatment (control) Dental evaluation at baseline, 3, 6, and 9 months. |
Experimental: Intensive Treatment Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit. | Procedure: Intensive Treatment Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit. |
Criterio de elegibilidad
Edades elegibles para estudiar | 60 Years A 60 Years |
Sexos elegibles para estudiar | All |
Acepta voluntarios saludables | si |
Criterios | Inclusion Criteria: - Age equal to or greater than 65 years. - Body Mass Index 18-35 kg/m2 - Mild to moderate periodontitis - Mild to moderate cognitive impairment on Montreal Cognitive Assessment (MoCA) -range greater than or equal to 17 and less than or equal to 26 (i.e., range from 17-26). - Detectable carotid plaque and carotid artery stenosis <70% as diagnosed by doppler ultrasound. - Able to perform prescribed dental hygiene and travel to medical center as required to participate in the study. Exclusion Criteria: - Inability to provide informed consent. - Subjects with inability to perform cognitive and other research testing - Prior stroke, depression (CESD >16), neurologic or psychiatric disease that would affect cognitive testing, participation, and compliance to the research study. - Subjects requiring chronic treatment with systemic corticosteroids or other systemic immunosuppressive drugs or drugs that would affect the dental treatments in the protocol are excluded. - Subjects requiring essential dental care (e.g., treatment for grossly decayed teeth, broken teeth, dental abscesses, peri-apical infections, other dental infections). - Inability to perform FDG-PET due to renal disease (eGFR <30 mL/min/1.75m2). - Receiving anticoagulant therapy (Warfarin) with an INR greater than 3.3 at time of dental treatment or with a bleeding disorder, or other diseases that may interfere with dental therapy. - Subjects with medical conditions that the clinicians feel would limit their ability to participate. |
Salir
Medidas de resultado primarias
1. Changes in performance on Montreal Cognitive Assessment (MoCA) [1 year]
Medidas de resultado secundarias
1. Presence of oral bacteria in saliva and dental plaque samples [1 year]
2. Presence of bacteria in stool samples [1 year]
3. Systemic inflammation [1 year]
4. Change from baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) [1 year]
5. Changes in performance on Wechsler Adult Intelligence Scale (WAIS)-III Digit Span subtest [1 year]
6. Changes in performance on Hopkins Verbal Learning Test [1 year]
7. Changes in performance on Brief Visuospatial Memory test [1 year]
8. Changes in performance on Trail Making Test (A+B) [1 year]
9. Changes in performance on Controlled Oral Word Association Test [1 year]
10. Changes in performance on Boston Naming Test [1 year]
11. Changes in performance on Modified Wisconsin Card Sorting Test [1 year]
12. Changes in performance on Grooved Pegboard Test [1 year]
13. Changes in Composite Cognitive Function Score [1 year]